首页> 美国卫生研究院文献>Journal of Clinical Oncology >BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor RAF Kinase and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)
【2h】

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor RAF Kinase and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)

机译:最佳:一项针对晚期肾细胞癌的血管内皮生长因子RAF激酶和雷帕霉素联合靶向治疗与贝伐单抗索拉非尼和替米罗莫司联合靶向治疗的随机II期临床研究-ECOG-ACRIN癌症研究小组的一项试验(E2804)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeOn the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these classes were hypothesized to improve treatment outcomes relative to single-agent VEGF pathway blockade.
机译:目的基于证据表明对血管内皮生长因子(VEGF)受体抑制的抗性是由缺氧驱动的残留VEGF和其他促血管生成因子引起的,假设相对于单药VEGF途径阻断剂,将这些类别的药物组合用于改善治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号